Using lab drug tests to help pick treatment for hard-to-treat brain tumors
Official title: Pharmacoscopy for Patients With Refractory Primary Brain Tumors
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study tests whether lab tests of drugs can help choose a treatment for each person.
Read our full plain-language summary
What the trial team says
Advanced technology of ex vivo drug profiling referred to as pharmacoscopy may allow to identify novel drugs for the treatment of glioblastoma and other refractory brain tumors at an individual patient level. This personalized therapeutic approach was developed and validated in pre-clinical glioma models. With the current research proposal, we seek to establish feasibility for a clinical interventional trial for patients with refractory primary brain tumors that is based on pharmacoscopy-guided selection of treatment. The study is supported by an unrestricted grant from Anti Cancer Fund.
Key facts
- Registry number
- NCT06804655
- Stage of testing
- Phase 2
- Conditions studied
- Brain (Nervous System) Cancers, Glioblastoma, Glioma, Ependymoma, Medulloblastoma, Meningioma, Rare Primary Brain Tumors, Rare CNS Primary Tumors
Where it is running
This trial lists 3 sites.
-
Basel-Landschaft
- University Hospital Basel (Basel)
-
Canton of St. Gallen
- Cantonal Hospital St Gallen (Sankt Gallen)
-
Canton of Zurich
- University Hospital Zurich (Zurich)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.